Key Problems Behind Teva's Lackluster 2013
While the pharmaceutical space has been generating hefty returns for investors since the start of the year, shares of Teva Pharmaceuticals are up a mere 2.7%. Compare that with Dow component Pfizer, which has soared almost 14%, and generic-drug maker Mylan, up 42% since the start of 2013, and it's clear that something serious is muting Teva's growth. In the following video from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso discuss the major competitive threats confronting Teva today.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Key Problems Behind Teva's Lackluster 2013 originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.